ImmunityBio Inc.
ImmunityBio Inc. logo
IBRX

ImmunityBio Inc. (IBRX)

$5.683.57%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$5.61
Day's Range
$5.93
$2.6
52-Week Range
$7.99
1 month return13.83%
3 month return25.94%
1 year return5.65%
5 year return82.52%

Company Information

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
OrganizationImmunityBio Inc.
Employees760
CEODr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc.
IndustryHealthcare

Analyst Recommendation

based on 8 analysts ratings

Buy
87%
Buy
12%
Hold
0%
Sell

Based on 8 Wall street analysts offering stock ratings for ImmunityBio Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 58.45%

Current

$5.68

Target

$9.0

Recommendation Trend

Based on 8 analyst

Current1M Ago3M Ago
Buy
7
7
6
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
2.4B
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.94
Wall Street Target Price
9.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.0
Enterprise Value
3.1B
Enterprise Value/Revenue
5556.23
Enterprise Value/Ebitda
-8.98

Technicals

50 Day MA
5.28
200 Day MA
4.81

Institutional Holdings

Vanguard Group Inc

2.02%

State Street Corporation

1.66%

BlackRock Inc

1.55%

Geode Capital Management, LLC

0.39%

Millennium Management LLC

0.29%

JPMorgan Chase & Co

0.29%

Discover more

Frequently Asked Questions

What is ImmunityBio Inc. share price today?

Can Indians buy ImmunityBio Inc. shares?

How can I buy ImmunityBio Inc. shares from India?

Can Fractional shares of ImmunityBio Inc. be purchased?

What are the documents required to start investing in ImmunityBio Inc. stocks?

What are today’s High and Low prices of ImmunityBio Inc.?

What are today’s traded volumes of ImmunityBio Inc.?

What is today’s market capitalisation of ImmunityBio Inc.?

What is the 52 Week High and Low Range of ImmunityBio Inc.?

How much percentage ImmunityBio Inc. is down from its 52 Week High?

How much percentage ImmunityBio Inc. is up from its 52 Week low?

What are the historical returns of ImmunityBio Inc.?

Who is the Chief Executive Officer (CEO) of ImmunityBio Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*